Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KURA
- Price
- 5.62
- Stock movement down
- -0.14 (-2.43%)
- Company name
- Kura Oncology Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 437.03M
- Ent value
- 442.62M
- Price/Sales
- 344.12
- Price/Book
- 1.03
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 3.94%
- 1 year return
- -72.40%
- 3 year return
- -30.51%
- 5 year return
- -6.70%
- 10 year return
- -
Last updated: 2025-04-09
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KURA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 344.12 |
| Price to Book | 1.03 |
| EV to Sales | 348.52 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 77.76M |
| EPS (TTM) | -2.27 |
| FCF per share (TTM) | -1.95 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.27M |
| Gross profit (TTM) | 620.00K |
| Operating income (TTM) | -217.50M |
| Net income (TTM) | -197.55M |
| EPS (TTM) | -2.27 |
| EPS (1y forward) | -1.91 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 48.82% |
| Operating margin (TTM) | -17126.14% |
| Profit margin (TTM) | -15555.28% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 49.48M |
| Net receivables | 0.00 |
| Total current assets | 463.19M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 10.48M |
| Total assets | 478.84M |
| Accounts payable | 3.01M |
| Short/Current long term debt | 16.63M |
| Total current liabilities | 40.37M |
| Total liabilities | 55.07M |
| Shareholder's equity | 423.77M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -169.12M |
| Capital expenditures (TTM) | 116.00K |
| Free cash flow (TTM) | -169.24M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -46.62% |
| Return on Assets | -41.26% |
| Return on Invested Capital | -45.42% |
| Cash Return on Invested Capital | -38.91% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.96 |
| Daily high | 6.12 |
| Daily low | 5.55 |
| Daily Volume | 1.01M |
| All-time high | 41.62 |
| 1y analyst estimate | 28.57 |
| Beta | 0.86 |
| EPS (TTM) | -2.27 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 Jun 2025 |
Downside potential
Loading...
Downside potential data
| KURA | S&P500 | |
| Current price drop from All-time high | -86.50% | -19.00% |
| Highest price drop | -87.15% | -56.47% |
| Date of highest drop | 5 Jul 2016 | 9 Mar 2009 |
| Avg drop from high | -50.52% | -11.07% |
| Avg time to new high | 58 days | 12 days |
| Max time to new high | 1085 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
437.03M
Marketcap category
Small-cap
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Employees
142
Website
Investor relations
-
SEC filings
CEO
Troy E. Wilson
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page